Overview

Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma

Status:
Active, not recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

This clinical trial will evaluate the safety and feasibility of a humanized OX40 agonist, MEDI0562, in the pre-operative setting for patients with head and neck squamous cell carcinoma or melanoma.

Phase:

Phase 1

Details

Lead Sponsor:

Providence Health & Services

Collaborators:

MedImmune LLC
Providence Cancer Center, Earle A. Chiles Research Institute